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Institute, Troy, NY 12180) CLYDE SMITH (Stanford Linear Accelerator Center, Menlo Park, 
CA 94025) 
 
Guiana Extended-Spectrum-1 (GES-1) and Aminoglycoside phosphotransferase (2’’)-Ic 
(APH(2’’)-Ic) are two bacteria-produced enzymes that essentially perform the same task: they 
provide resistance to an array of antibiotics. Both enzymes are part of a growing resistance 
problem in the medical world. In order to overcome the ever-growing arsenal of antibiotic-
resistance enzymes, it is necessary to understand the molecular basis of their action. Accurate 
structures of these proteins have become an invaluable tool to do this. Using protein 
crystallography techniques and X-ray diffraction, the protein structure of GES-1 bound to 
imipenem (an inhibitor) has been solved. Also, APH(2’’)-Ic has been successfully crystallized, 
but its structure was unable to be solved using molecular replacement using APH(2’’)-Ib as a 
search model. The structure of GES-1, with bound imipenem was solved to a resolution of 1.89Å, 
and though the inhibitor is bound with only moderate occupancy, the structure shows crucial 
interactions inside the active site that render the enzyme unable to complete the hydrolysis of the 
β-lactam ring. The APH(2’’)-Ic dataset could not be matched to the model, APH(2’’)-Ib, with 
which it shares 25% sequence identity. The structural information gained from GES-1, and 
future studies using isomorphous replacement to solve the APH(2’’)-Ic structure can aid directly 
to the creation of novel drugs to combat both of these classes of resistance enzymes. 
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Introduction 
For almost as long as bacteria have existed, they have waged wars against each other 
using an arsenal of chemicals which attack specific cellular processes necessary for their survival. 
In turn, it was necessary to have some way of preventing these chemicals from harming their 
maker, as well as have a defense against the antibiotics produced by other bacteria. In this way, 
antibiotic resistance was born and has advanced (with help from humans) to where it is today. 
Two such resistance proteins are the subject of this study. Protein crystallographic analysis is 
used to understand these types of proteins’ enzymatic mechanisms, with the ultimate goal of 
creating novel drugs which will either deactivate these enzymes or bypass their action 
completely.  
The general class of β-lactamases has been a part of antibiotic resistance since the 
beginning of the wide-spread use of antibiotics. The more recent arrival of extended-spectrum β-
lactamases (ESBLs) has added to this problem. One of the most recent families of ESBLs to be 
discovered is the Guiana Extended-Spectrum (GES) family [1]. The protein sequence of the GES 
proteins has significant differences from other β-lactamases of the same class [2]. The 
classification of “extended-spectrum” resistant β-lactamases refers to the fact that they are able 
to hydrolyze (deactivate) the type of β-lactam antibiotics designed to resist hydrolysis by β-
lactamases identified previously, often referred to as “last resort” antibiotics. The β-lactam 
family of antibiotics, which include the penicillins, cephalosporins, carbapenems, and 
monobactams, act by disabling cell-wall biosynthesis proteins, namely transpeptidases, which 
are responsible for the construction and modification of a peptidoglycan layer surrounding the 
cell membrane [3]. The way in which β-lactamases affect the action of these types of antibiotics 
is by hydrolyzing the β-lactam ring structure. Within the β-lactamase family, there are four 
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classes: A, B, C, and D [4]. The GES family is a class A β-lactamase, and is further classified as 
a third generation carbapenemase. The general structure of carbapenems is shown in Figure 1. 
The protein of interest in this study, GES-1, shows strong activity against most carbapenems, 
with some exceptions such as imipenem (structure shown in Figure 1) and specific inhibitors 
clavulanic acid, tazobactam, and sulfobactam [2]. The interesting part about its resistance profile 
is that while it is inhibited by imipenem, two other point mutants, namely GES-2 and GES-5, 
show 100-fold and 400-fold increases respectively in hydrolysis of imipenem [5]. The results of 
this structural study will aim to answer the question as to why these point mutants show such 
drastic differences in their activity towards imipenem.  
 Aminoglycosides are a second type of antibiotic used in medicine today. This class of 
antibiotics inhibits bacterial growth by binding to ribosome active sites, thereby halting protein 
synthesis [6]. With this second type of antibiotic comes a separate class of resistance enzymes. In 
general, they are called transferases, as they catalyze the transfer of a specific functional group to 
the antibiotic, thereby deactivating it. Aminoglycoside phosphotransferases (APH) are one 
member of this family of enzymes. APH enzymes transfer a phosphate to a particular hydroxyl 
group of the aminoglycoside antibiotic in an ATP-mediated fashion [7]. There are many isoforms 
of APH proteins, each classified by which hydroxyl group they phosphorylate (identified by a 
number in parenthesis), and the type of antibiotics they show activity against. For example, the 
enzyme in this study, APH(2’’)-Ic, phosphorylates the 2’’ hydroxyl of  gentamicin, kanamycin, 
and tobramycin (see Figure 2 for some example structures). Of the APH enzymes, three others 
have had their crystal structures solved, including APH(2’’)-Ib, APH(3’)-IIa and APH(3’)-III [6, 
8]. Several variants were used to attempt to grow crystals for this protein, including the wild-type 
and several mutants (two single and one double), with and without nucleotide (GTP) bound. By 
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working out the conditions for crystallizing APH(2’’)-Ic, though the structure was unable to be 
solved with molecular models, this study will aid in speeding up the process for future studies 
using alternative techniques (e.g. isomorphous replacement) for solving its structure.  
 
Materials and Methods 
Protein crystallization 
 For all of the APH(2’’)-Ic variants, initial coarse screens were performed using 
commercially available sparse-matrix screens (Crystal Screens I and II, Hampton Research) 
using the sitting drop method. One condition from Crystal Screen I [30% PEG 4000, 0.1M Tris 
HCl pH 8.5, at 15°C] resulted in crystals for F108L, wild-type, and double mutant variants (all 
bound GTP). Further fine screening of the F108L mutant using the hanging drop method resulted 
in crystals suitable for diffraction. Crystals grew as clusters of thin plates in 2μL drops 
containing protein in 25mM HEPES buffer (pH 7.6), 1mM DTT, and 1mM Mg2GTP, at a protein 
concentration of 8.8 mg/ml. The drops with the three crystals used for data analysis contained a 
1:1 mixture of protein to solution, one in 20% and two in 23% PEG 4000, all with 0.25M MgCl2, 
and 0.1M Tris HCl (pH 8.5), with the first (20% PEG) grown at 15°C and the other two (23% 
PEG) grown at 22°C for 3 days before harvesting. In addition, later fine screening using the 
wild-type protein produced similar crystals (flat and clustered), in conditions which included 23-
25% PEG 4000, 0.2M MgCl2, 0.1M Tris HCl (pH 8.5), at 22°C.  
 
Data collection and processing 
  The data previously collected for the imipenem-bound GES-1 protein was processed 
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using MOSFLM [9], and merged and scaled with SCALA [10] from the CCP4 suite of programs 
[11]. Data collection statistics can be found in Table 1.  
Data from the APH(2’’)-Ic crystals were collected at BL11-1 at the Stanford Synchrotron 
Radiation Laboratory (SSRL). The crystals used were flash frozen in liquid nitrogen before data 
collection. Earlier data analysis showed the crystals belonged to the monoclinic C2 space group, 
with unit cell parameters a = 81.77Å, b = 54.28Å, c = 77.42Å, and β = 108.97°. The calculated 
Matthews coefficient was 2.38Å/Da, indicating one molecule in the asymmetric unit.  Additional 
data collection statistics can be found in Table 1.  
 
Molecular replacement and refinement 
 Molecular replacement of GES-1 (bound imipenem) was carried out using COOT [12], 
utilizing the previously solved GES-1 structure [5] as the starting model. Refinements were done 
using the program REFMAC [13], as part of the CCP4 software, using data between 20- and 
1.89-Ǻ. A random five percent of the data set was left out as a test set (for the calculation of 
Rfree). After 10 rounds of refinements, the R-factor and Rfree converged to 15.8 and 21.9% 
respectively.  
 Molecular replacement of APH(2’’)-Ic was carried out using the program MOLREP [14], 
using the previously solved structure of APH(2’’)-Ib as a search model. The two proteins share 
about 25% sequence identity, and the model was modified so as to replace the unconserved 
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Results: 
Structural Determination of APH(2’’)-1c 
Starting from the initial screenings, several of the APH(2’’)-Ic variants exhibited fast-
formed, spiky crystal formation early on in a solution containing 30% PEG 4000, 0.2M MgCl2, 
and 0.1M Tris HCl (pH 8.5) at 15°C from Crystal Screen I. Initial tests provided proof that the 
crystals were indeed protein, and thereafter fine screening to refine crystal formation began. 
Numerous conditions were tested to slow down crystal formation, and the best results arose from 
the lower PEG concentrations, the same pH, and similar or slightly higher salt concentrations. 
Tests on temperature as a factor gave mixed results, with 4°C giving no useful crystals, 15°C 
resulting in the several useful crystals, and 22°C giving fewer, but better formed crystals. Large 
crystals formed as several flat sheets stuck together at a point, and when mounting these crystals, 
the sheets separated fairly easily and could be mounted individually. Useful datasets were 
collected from three crystals, one with 20% PEG 4000 (grown at 15°C) and two with 23% PEG 
4000 (grown at 22°C), all with 0.1M Tris HCl (pH8.5) and 0.25M MgCl2. So far there is no 
indication as to which, if any, dataset will yield the best results in finding the structure.  
 The APH(2’’)-Ic crystals, namely the F108L mutant, belongs to the space group C2, with 
one molecule in the asymmetric unit. Efforts to solve the three-dimensional structure using 
APH(2’’)-Ib have so far failed to give a reasonable solution to the structure.  
 Using the wild-type APH(2’’)-Ic, fine screening of the crystallization conditions resulted 
in crystals comparable in quality to those used to collect datasets from in the mutant. These 
conditions included 23, 24, and 25% PEG 4000, 0.2M MgCl2, and 0.1M Tris HCl (pH 8.5), at 
22°C. Datasets have not yet been taken from these crystals, as the synchrotron was not in service.  
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Inhibitor-binding studies with GES-1 β-lactamase 
 The data was fit using the previously solved GES-1 structure. Some refinement statistics 
are given in Table 2. The active site residues that are proposed to interact with the inhibitor are 
present, including Ser64, Lys67, Glu98, and Glu161. The imipenem molecule showed moderate 
(~65%) occupancy for the active site, with the other fraction occupied by a sulfate group (a 
solvent molecule). Several features are still visible, including covalent bonding between Ser64 
side chain oxygen and the imipenem C7 atom, with a bond length of 1.40Å. The hydrolytic water 
molecule is also present, but only at lower occupancy (<40%) and forms a hydrogen bonding 
interaction with oxygen 62 of imipenem and Glu161.  
 
Discussion and Conclusion: 
 The solved structure of GES-1 with bound imipenem sheds some light on the reason for 
the differences in activity between GES-1 and the other GES proteins discovered later. GES-1, 
although showing the characteristic active site disulfide bond of the carbapenemase-hydrolyzing 
β-lactamases, is incapable of hydrolyzing imipenem, a typical carbapenem antibiotic, and is in 
fact inhibited by this molecule.  It has been shown that two point mutants of GES-1, Gly165Asn 
(called GES-2) and Gly165Ser (GES-5) [15, 16] have significant activity against imipenem. 
Although the imipenem molecule was bound with only ~65% occupancy, several interactions 
between the inhibitor and the active site residues were present. In the refined structure, covalent 
bonding between imipenem and Ser64 of GES-1 is clearly observed, giving rise to an acyl-
enzyme intermediate which is the first step in the hydrolysis of the β-lactam ring. In addition, 
there are several hydrogen bonding interactions with other active site residues. A few of these 
hydrogen bonding partners are shown in Figure 3. Additionally, the hydrolytic water molecule is 
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present in the active site, and has hydrogen bonding partners which include the imipenem and the 
side chains of Ser64 and Glu161. However, the hydrolytic water molecule, which plays a crucial 
role in completing the hydrolysis of the β-lactam ring, shows less than 40% occupancy for its site 
above the hydroxyethyl moiety of the imipenem molecule. This result suggests that the reason 
for the decrease in GES-1 catalytic activity against imipenem could be due to the fact that the 
essential hydrolytic water is not held tightly and is therefore not optimally positioned for attack 
on the acyl-enzyme intermediate. On the other hand, GES-2 and GES-5, having the point 
mutations G165N and G165S, respectively, provide an additional hydrogen bonding partner for 
the hydrolytic water. In these enzymes, the hydrolytic water molecule may be held in the correct 
position to facilitate hydrolysis of the acyl-enzyme. Future structural studies using GES-2 and 
GES-5 bound imipenem are necessary to provide further evidence for this explanation.  
The APH(2’’)-Ib model has so far proved to be an insufficient search model for 
molecular replacement against the APH(2’’)-1c dataset. In the APH(2’’)-Ib structure, the alpha 
domain is somewhat disordered, which suggests that the APH(2’’)-Ic alpha domain could also be 
disordered or have a different orientation. Perhaps because of this, the model could not yield a 
reasonable fit to the data. Further studies using protein bound with 8-bromo-ATP, multiple 
isomorphous replacement experiments, or the preparation and crystallization of 
selenomethionine-substituted wild-type APH(2’’)-Ic may provide ways around this problem.  
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Tables and Figures: 
Table 1: Data Collection Statistics for imipenem-GES-1 and APH(2”)-Ic 
 Imipenem-GES-1 APH(2”)-Ic 
Space group P21 C2 
Unit cell parameters (Å) a=42.796, b=81.192, 
c=71.892, β=102.18° 
a=82.4 , b=54.2, 
c=77.0, β=108.8° 
Resolution (Å) 20-1.89 2.15 
Unique reflections 38, 545 14, 484 
Total reflections 872,781 377, 107 
Rmerge (%) 10.8 9.4 
Completeness (%) 99.96 97.1 
I/σI (%) 5.1 6.4 
 
Table 2: Refinement Statistics for imipenem-GES-1 
Resolution range (Å) 20.0 – 1.89 
Number of protein residues 266 
Number of waters 547 
Average B value:  15.837 
R-factor/Rfree (%) 15.8 / 21.9 
rmsd bond lengths (Å) 0.015 
rmsd angles (°) 1.614 
 
    
General structure     Imipenem 
Figure 1: Chemical structures of carbapenems. 
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   Gentamicin     Kanamycin 
Figure 2: Chemical structures of some aminoglycosides.  
 
 
Figure 3: Electron density map of GES-1 active site, bound imipenem. Active site residues and 
water molecules are shown with blue electron density, while the inhibitor (imipenem) has its 
electron density shown in pink. 2Fo-Fc density maps are shown.  
